The FDA is now approving biomarker-informed therapies on a routine basis, yet there is significant disparity in patient access to molecular profiling that would match cancer patients to these targeted treatments. 

 

Canexia Health’s Brady Davis recently moderated a panel during the Precision World Medicine Conference (PMWC) in Philadelphia, leading a discussion around providing equitable access to molecular testing within health system settings, from making the business case to reimbursement.

 

The panelists were:

 

  • Thuy Phung  | University of South Alabama
  • Michael B Datto M.D., Ph.D.| DUHS Clinical Labs, Duke University Health System, Clinical Laboratories
  • Peter Hulick, M.D. FACMG | Mark R Neaman Ctr. For Personalized Medicine, Northshore University Health System

 

For key takeaways, read our blog post or watch the full discussion here. 

Back

Recent Resources

Blog

February 3, 2023

Cutting-edge precision oncology, where the patient is

The theme for this year’s World Cancer Day is Close the Care Gap. Health equity is a pillar of our work at Imagia Canexia Health. So today our Chief Medical Officer, Dr. David Huntsman, is opening the conversation to showcase how our community-centered approach to cancer care is improving access to genomic-driven cancer care for all.

Press

December 1, 2022

Holiday Lab Hours

The holiday season is around the corner and we would like to inform everyone of our operation schedule over Christmas and New Year.